Comparison of Triflusal and Aspirin for Prevention of Vascular Events in Patients After Cerebral Infarction by Jordi Matías-Guiu, José M. Ferro, José Alvarez-Sabín,

Slides:

Advertisements

Similar presentations

CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel.

Advertisements

* Based on post hoc analysis of individual outcome events (N=19,185). 1 Data on file, Sanofi Pharmaceuticals, Inc. 2 Gent M. Circulation. 1997; 96 (suppl):

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aspirin for the Prevention of Cardiovascular Events.

Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Dose Aspirin for Primary Prevention of Cardiovascular.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduced-Function CYP2C19 Genotype and Risk of Adverse.

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10):

Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Choice of Antithrombotic Therapy for Stroke Prevention.

Erythrocyte Promotion of Platelet Reactivity Decreases the Effectiveness of Aspirin as an Antithrombotic Therapeutic Modality by Juana Valles, M. Teresa.

Discontinuation of medication after nonfatal event: MI

From: Risks of Cardiovascular Adverse Events and Death in Patients with Previous Stroke Undergoing Emergency Noncardiac, Nonintracranial Surgery:The Importance.

Copyright © 2012 American Medical Association. All rights reserved.

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis Stavros Stavrakis, MD The American Journal.

LEADER trial: Primary Outcome

Volume 385, Issue 9985, Pages (June 2015)

Fatal and Nonfatal Cardiovascular Disease and the Use of Therapies for Secondary Prevention in a Rural Region of India by Rohina Joshi, Clara K. Chow,

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

Copyright © 2006 American Medical Association. All rights reserved.

Alfred A. Bartolucci, PhD, Michal Tendera, MD, George Howard, DrPH

Circ Cardiovasc Interv

Target Blood Pressure for Treatment of Isolated Systolic Hypertension in the Elderly by Toshio Ogihara, Takao Saruta, Hiromi Rakugi, Hiroaki Matsuoka,

Functional Recovery in Aged and Young Rats After Embolic Stroke

Risk of Recurrent Stroke in Patients With Silent Brain Infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) Imaging Substudy.

Association Between Mycoplasma Pneumonia and Increased Risk of Ischemic Stroke by Chia-Hung Chiang, Chin-Chou Huang, Wan-Leong Chan, Yu-Chun Chen, Tzeng-Ji.

Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.

by Thomas Monks, Martin Pitt, Ken Stein, and Martin James

Circ Cardiovasc Interv

Relative Distributions

Contribution of Stroke to the Cochrane Stroke Group Trials Register

Virtual Reality in Stroke Rehabilitation

Statin Treatment and Functional Outcome After Ischemic Stroke

by Beverly G. Windham, Michael E

Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke by.

Reflux Esophagitis and the Risk of Stroke in Young Adults

by Alexander Leaf, Christine M

Cancer in Young Adults With Ischemic Stroke

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Introduction The American Journal of Medicine

Trends in Stroke Rates, Risk, and Outcomes in the United States, 1988 to 2008 Margaret C. Fang, MD, MPH, Marcelo Coca Perraillon, MA, Kaushik Ghosh, PhD,

Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease Nina Raju, MD, MsC, Magdalena Sobieraj-Teague, MBBS, Jack Hirsh, MD,

Aspirin in the prevention of cancer – Author's reply

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Copyright © 2012, Elsevier Inc. All rights Reserved.

David Rosenthal, MD, Edgar Borrero, MD, Michael D. Clark, MD, Pano A

Potential mechanisms whereby statins may reduce the risk of stroke

Volume 385, Issue 9985, Pages (June 2015)

Copyright © 2013 Elsevier Inc. All rights reserved.

Copyright © 2012, Elsevier Inc. All rights Reserved.

Berger JS, et al. JAMA 2009;301:

Copyright © 2012, Elsevier Inc. All rights Reserved.

Copyright © 2013 Elsevier Inc. All rights reserved.

Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal.

Women’s Health Study: Baseline Characteristics Part 1

MATCH Results: Implications for the Internist

Modeling Functionality with Use Cases

Copyright © 2012, Elsevier Inc. All rights Reserved.

Characteristics of included studies

Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits? Luis Alejandro Asencio, MD, Jennifer J. Huang, DO,

Figure 2 Kaplan-Meier survival graphs for 10-year risks of overall and post-90-day recurrent ischemic stroke (IS) and death Kaplan-Meier survival graphs.

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

Copyright © 2012, Elsevier Inc. All rights Reserved.

Comparison of Baseline Characteristics by Primary End Point

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Copyright © 2013 Elsevier Inc. All rights reserved.

Jeffrey J. Teuteberg et al. JCHF 2015;3:

Copyright © 2012, Elsevier Inc. All rights Reserved.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Proportions of the social isolation—AMI and stroke excess risk mediated by biological, behavioural, socioeconomic and health-related factors. Proportions.

Kaplan-Meier event-free survival from ipsilateral stroke for patients with near occlusion, pooled data from the NASCET and ECST. The 3-year intention-to-treat.

Presentation transcript:

Comparison of Triflusal and Aspirin for Prevention of Vascular Events in Patients After Cerebral Infarction by Jordi Matías-Guiu, José M. Ferro, José Alvarez-Sabín, Ferran Torres, M. Dolores Jiménez, Aida Lago, and Teresa Melo Stroke Volume 34(4):840-848 April 1, 2003 Copyright © American Heart Association, Inc. All rights reserved.

Figure 1. Trial profile. Figure 1. Trial profile. ITT indicates intention to treat; PP, per protocol. Jordi Matías-Guiu et al. Stroke. 2003;34:840-848 Copyright © American Heart Association, Inc. All rights reserved.

Figure 2. Survival analysis of primary end point (nonfatal ischemic stroke, nonfatal AMI, vascular death). Figure 2. Survival analysis of primary end point (nonfatal ischemic stroke, nonfatal AMI, vascular death). Jordi Matías-Guiu et al. Stroke. 2003;34:840-848 Copyright © American Heart Association, Inc. All rights reserved.

Figure 3. Cumulative risk of any cerebral or major systemic hemorrhages. Jordi Matías-Guiu et al. Stroke. 2003;34:840-848 Copyright © American Heart Association, Inc. All rights reserved.